A case report of severe visceral beta2-microglobulin-derived amyloidosis without obvious joint symptoms or radiological findings in a chronic hemodialyzed patient with systemic lupus erythematosus

Ther Apher Dial. 2009 Jun;13(3):232-7. doi: 10.1111/j.1744-9987.2009.00696.x.

Abstract

Beta-2-microglobulin-derived amyloidosis (Abeta2M amyloidosis) is a critical complication for patients undergoing long-term renal replacement therapy. Osteoarticular lesions, rather than visceral organs, are susceptible to this type of amyloidosis, and the visceral form seems to occur at a relatively late stage. Herein, we report a case of severe visceral Abeta2M amyloidosis without obvious joint symptoms or radiological findings in a chronic hemodialyzed patient who had received long-term treatment with glucocorticoid steroids for systemic lupus erythematosus. It should be noted that prominent visceral Abeta2M amyloidosis can develop without any osteoarticular symptoms or radiological abnormalities in dialyzed patients undergoing prolonged glucocorticoid therapy.

Publication types

  • Case Reports

MeSH terms

  • Amyloidosis / etiology*
  • Amyloidosis / physiopathology
  • Female
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use
  • Humans
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Nephritis / therapy
  • Middle Aged
  • Renal Dialysis / adverse effects*
  • Severity of Illness Index
  • Time Factors
  • beta 2-Microglobulin / metabolism*

Substances

  • Glucocorticoids
  • beta 2-Microglobulin